立方制药
(003020)
| 流通市值：24.92亿 | | | 总市值：34.52亿 |
| 流通股本：1.38亿 | | | 总股本：1.91亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,125,115,398.63 | 769,332,113.02 | 333,618,253.5 | 1,900,789,181.92 |
| 营业收入 | 1,125,115,398.63 | 769,332,113.02 | 333,618,253.5 | 1,900,789,181.92 |
| 二、营业总成本 | 1,000,958,904.88 | 682,320,390.82 | 307,762,871.44 | 1,682,608,293.1 |
| 营业成本 | 338,419,569.21 | 219,061,736.7 | 103,396,947.09 | 922,201,876.52 |
| 税金及附加 | 16,659,556.84 | 11,671,815.73 | 4,804,848.6 | 18,335,254.81 |
| 销售费用 | 528,538,993.22 | 370,541,100.39 | 158,408,834.3 | 598,452,170.05 |
| 管理费用 | 63,906,891.95 | 44,822,686.14 | 18,046,458.59 | 61,957,320.43 |
| 研发费用 | 53,806,835.68 | 36,733,959.75 | 23,546,764.47 | 84,955,600.2 |
| 财务费用 | -372,942.02 | -510,907.89 | -440,981.61 | -3,293,928.91 |
| 其中:利息费用 | 926,622.88 | 832,408.32 | 230,375 | 1,281,276.05 |
| 其中:利息收入 | 1,666,307.9 | 1,369,710.82 | 855,219.77 | 4,650,814.35 |
| 加:公允价值变动收益 | 1,247,272.11 | 1,458,354.11 | 972,789.6 | 315,515.08 |
| 加:投资收益 | 9,025,245.56 | 5,267,272.34 | 3,433,225.39 | 27,485,243.74 |
| 资产处置收益 | 92,974.46 | 96,401.57 | - | - |
| 资产减值损失(新) | -9,054,141.15 | -9,553,286.58 | -2,070,274.62 | -9,201,004.38 |
| 信用减值损失(新) | -1,971,133.3 | -2,130,947.86 | -790,341.67 | -2,105,265.78 |
| 其他收益 | 8,066,987.99 | 5,046,061.76 | 1,614,338.33 | 20,594,831.9 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 131,563,699.42 | 87,195,577.54 | 29,015,119.09 | 255,270,209.38 |
| 加:营业外收入 | 456,195.12 | 395,084.24 | 237,277.21 | 3,145,360.29 |
| 减:营业外支出 | 699,739.71 | 647,455.13 | 244,053.46 | 998,827.95 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 131,320,154.83 | 86,943,206.65 | 29,008,342.84 | 257,416,741.72 |
| 减:所得税费用 | 15,663,621.35 | 10,950,599.24 | 1,552,821.39 | 23,534,161.97 |
| 六、净利润 | 115,656,533.48 | 75,992,607.41 | 27,455,521.45 | 233,882,579.75 |
| 持续经营净利润 | 115,656,533.48 | 75,992,607.41 | 27,455,521.45 | 233,882,579.75 |
| 归属于母公司股东的净利润 | 118,979,752.45 | 77,430,915.09 | 30,372,220.01 | 226,672,720.79 |
| 少数股东损益 | -3,323,218.97 | -1,438,307.68 | -2,916,698.56 | 7,209,858.96 |
| (一)基本每股收益 | 0.63 | 0.4 | 0.19 | 1.42 |
| (二)稀释每股收益 | 0.63 | 0.4 | 0.19 | 1.42 |
| 九、综合收益总额 | 115,656,533.48 | 75,992,607.41 | 27,455,521.45 | 233,882,579.75 |
| 归属于母公司股东的综合收益总额 | 118,979,752.45 | 77,430,915.09 | 30,372,220.01 | 226,672,720.79 |
| 归属于少数股东的综合收益总额 | -3,323,218.97 | -1,438,307.68 | -2,916,698.56 | 7,209,858.96 |
| 公告日期 | 2024-10-30 | 2024-08-31 | 2024-04-30 | 2024-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |